Related Experiment Video
Updated: May 9, 2026

Murine Model of CD40-activation of B cells
Published on: March 5, 2010
The CD40/CD40L system: a new therapeutic target for disease
Bikui Zhang1, Tian Wu, Min Chen
1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Insights
CD40/CD40 ligand (CD40L) interactions are crucial in cardiovascular diseases and immune responses. Understanding these pathways and current CD40/CD40L drugs can lead to new treatments for various conditions.
Area of Science:
- Immunology
- Cardiovascular Biology
- Pharmacology
Background:
- CD40/CD40 ligand (CD40L) interactions play a recognized role in atherothrombosis, immune responses to pathogens, and thrombosis.
- These interactions are implicated in atherosclerosis (AS) pathogenesis, destabilizing plaques via cytokine and matrix metalloproteinase induction.
- CD40/CD40L signaling also influences immune system disorders, oxidative stress, and key signaling pathways in immunological and cardiovascular systems.
Purpose of the Study:
- To review the established roles of CD40/CD40L interactions in health and disease.
- To discuss current therapeutic strategies targeting the CD40/CD40L pathway.
- To highlight the potential for developing novel therapeutics based on understanding CD40/CD40L signaling.
Main Methods:
- Literature review of studies on CD40/CD40L interactions.
- Analysis of current drugs targeting the CD40/CD40L system.
- Discussion of signaling pathways regulated by CD40/CD40L.
Main Results:
- CD40/CD40L interactions significantly impact plaque stability, immune responses, and thrombosis.
- Current drugs targeting CD40/CD40L are being investigated for various therapeutic applications.
- Understanding CD40/CD40L regulation is key to developing new treatments.
Conclusions:
- CD40/CD40L interactions are central to multiple pathological processes.
- Targeting the CD40/CD40L pathway offers therapeutic potential for diverse diseases.
- Further research into CD40/CD40L signaling can drive innovation in drug development.
Abstract:
The role of CD40/CD40 ligand (CD40L) interactions in atherothrombosis, in the response of the immune system to pathogens and in thrombosis is now widely accepted. A role for CD40-CD40L interactions has been identified in atherosclerosis (AS), and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors. CD40/CD40L interactions have also been implicated in immune system disorders. Recent studies have suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. Here, we discuss the current drugs that target the CD40/CD40L system, as understanding the roles and regulations of CD40/CD40L-mediated signal pathways by these drugs could facilitate the development of therapeutics that target diverse diseases.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
